The Food and Drug Administration on July 5 approved Edwards Lifesciences Corp.'s Inspiris Resilia aortic valve.
Here are three things to know.
- The valve is intended for use in surgical aortic valve replacement.
- The implant features anticalcification tissue properties, an expandable frame and capabilities for future valve-in-valve procedures.
- Edwards' Lifesciences will launch the heart valve in early 2018.
More articles on supply chain:
Precision benchmarking a panacea for purchased services savings
Vertex Pharma makes 1st price hike on cystic fibrosis drug
Novo Nordisk recalls insulin pen cartridge holders